Clinical trial
Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease. The ROADSTER 3 Study
NCT05365490 is registered in ClinicalTrials.gov with Silk Road Medical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease. The ROADSTER 3 Study
- Lead sponsor
- Silk Road Medical
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 1, 2022
- Completion date
- July 22, 2025
- Enrollment
- 344 (actual)
- Sites
- 53
Conditions
As the registry lists them; a condition with its own page is linked.